Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSC2100
- Development stage
- Preclinical
- Lead developer
- BiSiChem
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
BSC2100 is a preclinical-stage small molecule agonist of the Stimulator of Interferon Genes (STING) pathway, currently under development by BiSiChem. STING is a critical mediator of the innate immune system; its activation leads to the production of Type I interferons and other pro-inflammatory cytokines, which can stimulate a robust T-cell-mediated anti-tumor response. BiSiChem is developing BSC2100 both as a standalone small molecule therapeutic and as a potent payload for antibody-drug conjugates (ADCs), aiming to provide targeted delivery of STING activation directly to the tumor microenvironment to enhance efficacy and reduce systemic toxicity.
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on BSC2100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BSC2100.